Expiration Date: June 24, 2017
Media: Internet - based
This activity focuses on management strategies in ovarian cancer and features a series of short video interviews with leading experts in the treatment of ovarian cancer. The content and interviews are based on presentations given at Expert Perspectives in PARP Inhibition: Evolving Management Strategies in Ovarian Cancer, a CME-certified, ancillary satellite symposium held at the Annual Meeting on Women’s Cancer®.
CME Activity Table of Contents
- Mechanism of Action of PARP Inhibitors and Drug Resistance
- Current Landscape – PARP as a Single Agent
- Combination Therapy with PARP Inhibitors
- Where Have We Been with PARP in Ovarian Cancer and Where Are We Going?
Instructions For This Activity & Receiving Credit
This activity is directed toward medical oncologists, gynecologic oncologists, pathologists, radiation oncologists, and surgical oncologists who treat patients with ovarian cancer. Obstetrician/gynecologists, nurses, physician assistants, fellows, residents, and other healthcare professionals interested in the treatment of ovarian cancer may also participate.
At the conclusion of this activity, you should be better prepared to:
- Describe the emerging role of PARP inhibitors as single-agent therapies within the current treatment paradigm for recurrent ovarian cancer
- Discuss the role of genetic testing and the expansion of PARP inhibitors into treatment for patients outside of the BRCA-mutant population
- Discuss the mechanisms of action of PARP inhibitors
- Increase awareness of current ongoing clinical trials that are testing PARP inhibitors, including novel combination approaches
Faculty, Staff, and Planners' Disclosures
Michael J. Birrer, MD, PhD
Professor of Medicine, Harvard Medical School
Director, Gillette Center for Gynecologic Oncology
Massachusetts General Hospital
Disclosure: No relevant financial relationships with commercial interests.
Maurie Markman, MD
President, CTCA Medicine and Science
Cancer Treatment Centers of America
Disclosure: Consultant: Amgen, Celgene, CritiTech; Speaker's Bureau: Genentech, AstraZeneca.
Joyce Liu, MD, MPH
Assistant Professor of Medicine, Harvard Medical School
Physician, Dana-Farber Cancer Institute
Disclosure: Consultant: AstraZeneca; Investigational/Off-Label Use of Drugs or Device: Olaparib, Veliparib, Niraparib, Rucaparib, Talazoparib.
James Tate Thigpen, MD
Professor of Medicine
Director, Division of Hematology and Oncology
The University of Mississippi Medical Center
Disclosure: Speaker's Bureau: Amgen, Boehringer Ingelheim, Genentech, Janssen Biotech, AstraZeneca, Lilly.
The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests.
Disclosure Policy and Resolution of Conflicts of Interest (COI)
It is the policy of Physicians' Education Resource®, LLC, (PER®) to ensure fair balance, independence, objectivity, and scientific rigor in all of our CME/CE activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as a part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
Off-Label Disclosure and Disclaimer
This CME/CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of Physicians' Education Resource®, LLC, or any of the companies that provided commercial support for this activity.
Hardware And Software Requirements
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)
Minimum System Requirements (Windows)
- A Pentium-based PC or compatible computer
- At least 64MB of RAM
- Windows 95/98/NT/ME/2000/XP/Vista system software
- Screen resolution of 1024 x 786 or larger recommended
- PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise